🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Amit Mahipal

University Hospitals of Cleveland

ORCID: 0000-0002-1111-8333

Also affiliated with University Hospitals Seidman Cancer Center, Case Western Reserve University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers”.

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Journal of Clinical Oncology(2024)10.1200/jco-24-01383
N/A
1.1DataRank · unranked
51 citations

Gentry Teng King, Sarah Colby, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff +17 more

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4099
N/A
0DataRank · unranked
1 citations

Jesse G. Dixon, Hiral D. Parekh, Steven R. Alberts, Greg Yothers, Carmen J. Allegra +15 more

FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

Digestive Diseases and Sciences(2021)10.1007/s10620-021-07303-9
N/A
0DataRank · unranked
12 citations

Thomas DeLeon, James M. Bogenberger, Rish K. Pai, Heidi Kosiorek, Jun Yin +26 more

Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)

Investigational New Drugs(2021)10.1007/s10637-021-01090-w
N/A
0DataRank · unranked
10 citations

Nathan R. Foster, Amit Mahipal, Thomas Byrne, Joleen M. Hubbard, Alvin Silva +4 more

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma

Cancers(2022)10.3390/cancers14215173
N/A
0DataRank · unranked
16 citations

Jennifer Gile, Mathias Earl Palmer, Tyler Zemla, Daniel H. Ahn, Tanios Bekaii‐Saab +4 more

Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma

Targeted Oncology(2022)10.1007/s11523-022-00914-w
N/A
0DataRank · unranked
8 citations

Vanessa Wookey, Tyler Zemla, Qian Shi, Zhaohui Jin, Steven R. Alberts +7 more

P-70 Outcomes following FGFR inhibitor therapy in patients with cholangiocarcinoma: Multi-center single institution cohort experience

Annals of Oncology(2022)10.1016/j.annonc.2022.04.160
N/A
0DataRank · unranked
0 citations

Vanessa Wookey, Tyler Zemla, Q. Shi, Tanios Bekaii‐Saab, Nguyen H. Tran +2 more

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.lba490
N/A
0DataRank · unranked
99 citations

Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin +15 more

NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma

Annals of Surgical Oncology(2023)10.1245/s10434-023-13809-5
N/A
0DataRank · unranked
81 citations

Jessica M. Keilson, Hop S. Tran Cao, Manali Rupji, Amit Mahipal, Bruce Lin +6 more

Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study

Cancers(2023)10.3390/cancers15194867
N/A
0DataRank · unranked
8 citations

Jennifer Gile, Michael H. Storandt, Zhaohui Jin, Tyler Zemla, Nguyen H. Tran +2 more

Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps273
N/A
0DataRank · unranked
3 citations

David L. Bajor, Amr Mohamed, Sakti Chakrabarti, Jane Reese, Hillard M. Lazarus +4 more

Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial

Clinical Lung Cancer(2024)10.1016/j.cllc.2024.12.003
N/A
0DataRank · unranked
4 citations

A. Martinez Bueno, Christophe Dooms, Komal Jhaveri, Maria de Miguel, Sarina A. Piha‐Paul +12 more

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma

JAMA Oncology(2020)10.1001/jamaoncol.2020.4930
N/A
0DataRank · unranked
200 citations

Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Daniel Almquist, Syeda A. Mina, Jehad Almasri +13 more

Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma

Endocrine Related Cancer(2025)10.1530/erc-24-0142
N/A
0DataRank · unranked
5 citations

Þorvarður R. Hálfdánarson, Erin E. Carlson, Kari G. Rabe, Amit Mahipal, Shounak Majumder +9 more